neostigmin panpharma 0,5 mg/ml otopina za injekciju
panpharma, z.i. du clairay, luitre, francuska - neostigminijev metilsulfat - otopina za injekciju - 0,5 mg/ml - urbroj: 1 ml otopine za injekciju sadrži 0,5 mg neostigminijeva metilsulfata
heparin panpharma 5 000 iu/ml otopina za injekciju/infuziju
panpharma, z.i. du clairay, luitre, francuska - heparinnatrij - otopina za injekciju/infuziju - 5 000 iu/ml - urbroj: 1 ml otopine sadrži 5 000 iu heparinnatrija; jedna bočica s 5 ml otopine sadrži 25 000 iu heparinnatrija
ropivakain bioq pharma 2 mg/ml otopina za infuziju u sustavu za primjenu
bioq pharma b.v., prins bernhardplein 200, amsterdam, nizozemska - ropivakainklorid hidrat - otopina za infuziju u sustavu za primjenu - 2 mg/ml - urbroj: 1 ml otopine za infuziju sadrži ropivakainklorid hidrat što odgovara 2 mg ropivakainklorida
dobutamin panpharma 250 mg/20 ml koncentrat za otopinu za infuziju
panpharma, z.i. du clairay, luitre, francuska - dobutaminklorid - koncentrat za otopinu za infuziju - 250 mg/20 ml - urbroj: 1 bočica sa 20 ml sadrži 250 mg dobutamina u obliku 280,2 mg dobutaminklorida
budesonide/formoterol teva pharma b.v.
teva pharma b.v. - budesonide, formoterol - astma - lijekovi za opstruktivne plućne bolesti dišnih putova, - budesonid / formoterol teva pharma b. je indiciran u odrasloj dobi od 18 godina i stariji. asthmabudesonide/Формотерола tewa pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
olopatadin unimed pharma 1 mg/ml kapi za oko, otopina
unimed pharma spol. s r.o., orieskova 11, bratislava, slovačka - olopatadinklorid - kapi za oko, otopina - 1 mg/ml - urbroj: 1 ml otopine sadrži 1 mg olopatadina, što odgovara 1,11 mg olopatadinklorida
bromhexine sopharma 4 mg/5 ml sirup
unifarm d.o.o. - bromheksin - sirup - 4 mg/5 ml - 5 ml sirupa sadrži: 4 mg bromheksinhidrohlorida
cinacalcet accordpharma
accord healthcare s.l.u. - cinakalcet hidroklorid - hiperparatireoidizam - homeostaza kalcija - sekundarni hyperparathyroidismadultstreatment sekundarni hiperparatireoidizam (atg) u odraslih bolesnika s terminala bubrega (esrd) na održavanje диализной terapija. vrtić populationtreatment sekundarni hiperparatireoidizam (atg) u djece u dobi od 3 godina i stariji sa terminala fazi zatajenja bubrega (esrd), koji se nalazi na održavanje диализной terapije, u kojem sekundarni atg nije adekvatno kontroliran pomoću razine terapije (vidi odjeljak 4. Цинакалцет accordpharma može se koristiti kao dio zdravstvenog stanja, uključujući i fosfatnih veziva i/ili vitamina d, steroli, na odgovarajući način (vidi odjeljak 5. karcinom parathyroid žlijezde i primarni hiperparatireoidizam u adultsreduction razvoj гиперкальциемии kod odraslih pacijenata s карциномой parathyroid. primarni atg, za koje паратиреоидэктомия će biti drugačije, na temelju razine kalcija u serumu (kao što je definirano u relevantnim smjernicama za liječenje), ali u kojima паратиреоидэктомия nije klinički ili je kontraindicirano.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastična sredstva - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.